Extrapulmonary Neuroendocrine Carcinoma

Extrapulmonary Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

315 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 104
Recruiting: 46
Ph III recruiting: 1
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (50)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05358938	Exercise to Boost Response to Checkpoint Blockade Immunotherapy	active not recruiting	Early Phase 1	22	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Sep 15, 2026	clinicaltrials
NCT03647657	177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer	completed	Early Phase 1	8	University Hospital, Basel, SwitzerlandOTHER	1	Feb 10, 2022